Patent Assignment
Reel/Frame 058726/0493
Assignment of Assignor's Interest
Recorded: 2022-01-21
Pages: 4
Assignor
CHARLES RIVER LABORATORIES, INC.
Executed: 2021-09-09
Assignee
SHIRE HUMAN GENETIC THERAPIES, INC.
300 SHIRE WAY, LEXINGTON, MASSACHUSETTS, 02421
Covered Property
(1)
Plasma Kallikrein Inhibitors and Uses Thereof
Patent:
11,787,796 →
Application:
17/024,437 →
Publication:
US 2021/0078999
PCT:
PCT/US2020/051293 ↗
Related Assignments
(7)
Other recorded transfers of the patent in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 30, 2021
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055766/0572 →
Assignment of Assignor's Interest
Jan 21, 2022
From: ELLARD, JOHN MARK; RAE, ALASTAIR
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 058726/0408 →
Assignment of Assignor's Interest
Jan 21, 2022
From: PAPAIOANNOU, NIKOLAOS; TRAVINS, JEREMY MARK; FINK, SARAH JOCELYN
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 058726/0446 →
Assignment of Assignor's Interest
Jan 21, 2022
From: FINK, SARAH JOCELYN
To: BIODURO LLC
Reel/Frame 058726/0395 →
Assignment of Assignor's Interest
Jan 21, 2022
From: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
To: CHARLES RIVER LABORATORIES, INC.
Reel/Frame 058726/0499 →
Assignment of Assignor's Interest
Jan 21, 2022
From: BIODURO LLC
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 058726/0476 →
Assignment of Assignor's Interest
Mar 7, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 059185/0461 →